| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colitis | 17 | 2020 | 156 | 4.160 |
Why?
|
| Panax | 11 | 2020 | 31 | 3.600 |
Why?
|
| Colonic Neoplasms | 11 | 2015 | 299 | 2.850 |
Why?
|
| Hydrolases | 7 | 2015 | 20 | 2.560 |
Why?
|
| Colitis, Ulcerative | 9 | 2020 | 53 | 2.430 |
Why?
|
| Plant Extracts | 10 | 2020 | 122 | 2.370 |
Why?
|
| Tumor Suppressor Protein p53 | 16 | 2016 | 231 | 2.100 |
Why?
|
| Inflammation | 23 | 2017 | 1030 | 2.060 |
Why?
|
| Antioxidants | 6 | 2020 | 304 | 1.800 |
Why?
|
| Ornithine | 5 | 2015 | 9 | 1.650 |
Why?
|
| Phytotherapy | 6 | 2020 | 53 | 1.630 |
Why?
|
| Nitric Oxide | 13 | 2012 | 382 | 1.540 |
Why?
|
| DNA Damage | 9 | 2015 | 190 | 1.420 |
Why?
|
| Colorectal Neoplasms | 7 | 2020 | 560 | 1.260 |
Why?
|
| Apoptosis | 19 | 2015 | 1641 | 1.230 |
Why?
|
| Dextran Sulfate | 10 | 2017 | 88 | 1.220 |
Why?
|
| Stilbenes | 6 | 2011 | 57 | 1.050 |
Why?
|
| Gastrointestinal Microbiome | 3 | 2020 | 121 | 0.890 |
Why?
|
| Diynes | 2 | 2020 | 6 | 0.860 |
Why?
|
| Stress, Psychological | 2 | 2020 | 824 | 0.860 |
Why?
|
| NF-E2-Related Factor 2 | 3 | 2020 | 110 | 0.860 |
Why?
|
| Fatty Alcohols | 2 | 2020 | 14 | 0.860 |
Why?
|
| Mice, Inbred C57BL | 20 | 2020 | 2791 | 0.840 |
Why?
|
| Animals | 45 | 2020 | 20880 | 0.840 |
Why?
|
| Hexanes | 2 | 2012 | 7 | 0.840 |
Why?
|
| Nitric Oxide Synthase Type II | 15 | 2016 | 201 | 0.840 |
Why?
|
| Inflammation Mediators | 4 | 2011 | 244 | 0.820 |
Why?
|
| Colon | 8 | 2016 | 168 | 0.820 |
Why?
|
| Neoplasms | 9 | 2015 | 1664 | 0.790 |
Why?
|
| Mice | 33 | 2019 | 8474 | 0.780 |
Why?
|
| Diet, Western | 1 | 2020 | 17 | 0.720 |
Why?
|
| Citrulline | 3 | 2015 | 9 | 0.710 |
Why?
|
| Dietary Supplements | 3 | 2012 | 331 | 0.700 |
Why?
|
| Enzyme Inhibitors | 2 | 2013 | 659 | 0.650 |
Why?
|
| Macrophages | 10 | 2016 | 647 | 0.640 |
Why?
|
| Oxidative Stress | 4 | 2020 | 718 | 0.630 |
Why?
|
| Protein Processing, Post-Translational | 4 | 2015 | 284 | 0.570 |
Why?
|
| Quinacrine | 1 | 2016 | 10 | 0.570 |
Why?
|
| Drug Repositioning | 1 | 2016 | 8 | 0.560 |
Why?
|
| MicroRNAs | 4 | 2015 | 447 | 0.560 |
Why?
|
| Retinoblastoma Protein | 2 | 2007 | 75 | 0.550 |
Why?
|
| Amidines | 2 | 2013 | 7 | 0.540 |
Why?
|
| Antimalarials | 1 | 2016 | 71 | 0.540 |
Why?
|
| Diet | 5 | 2020 | 514 | 0.540 |
Why?
|
| Lymphocytes | 3 | 2012 | 228 | 0.520 |
Why?
|
| Anti-Inflammatory Agents | 5 | 2015 | 234 | 0.520 |
Why?
|
| Humans | 54 | 2020 | 68549 | 0.520 |
Why?
|
| DNA Repair | 7 | 2009 | 127 | 0.500 |
Why?
|
| Biomedical Research | 1 | 2018 | 310 | 0.480 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2015 | 88 | 0.470 |
Why?
|
| Protein-Arginine Deiminases | 4 | 2015 | 5 | 0.460 |
Why?
|
| Fruit | 2 | 2012 | 86 | 0.460 |
Why?
|
| Vegetables | 2 | 2012 | 76 | 0.460 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2011 | 126 | 0.450 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 1026 | 0.440 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2013 | 37 | 0.440 |
Why?
|
| Cytokines | 6 | 2015 | 866 | 0.430 |
Why?
|
| Reactive Nitrogen Species | 3 | 2012 | 32 | 0.430 |
Why?
|
| Obesity | 1 | 2020 | 1074 | 0.420 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2013 | 756 | 0.410 |
Why?
|
| Malus | 1 | 2011 | 4 | 0.410 |
Why?
|
| Beverages | 1 | 2012 | 50 | 0.400 |
Why?
|
| Polyphenols | 1 | 2011 | 34 | 0.400 |
Why?
|
| Disease Models, Animal | 10 | 2017 | 2550 | 0.390 |
Why?
|
| HCT116 Cells | 4 | 2020 | 63 | 0.390 |
Why?
|
| Cell Line, Tumor | 9 | 2015 | 1851 | 0.390 |
Why?
|
| Cyclooxygenase 2 | 5 | 2016 | 160 | 0.370 |
Why?
|
| Gastrointestinal Agents | 1 | 2011 | 51 | 0.370 |
Why?
|
| Adamantane | 1 | 2010 | 40 | 0.360 |
Why?
|
| Signal Transduction | 9 | 2015 | 2689 | 0.360 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2008 | 226 | 0.350 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2008 | 199 | 0.350 |
Why?
|
| NF-kappa B | 5 | 2012 | 432 | 0.340 |
Why?
|
| E2F1 Transcription Factor | 2 | 2007 | 44 | 0.340 |
Why?
|
| Age of Onset | 2 | 2020 | 188 | 0.330 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2010 | 200 | 0.330 |
Why?
|
| Genes, p53 | 4 | 2004 | 41 | 0.320 |
Why?
|
| Pyridines | 1 | 2010 | 261 | 0.320 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 239 | 0.320 |
Why?
|
| Cell Line | 9 | 2016 | 1752 | 0.310 |
Why?
|
| Complementary Therapies | 1 | 2008 | 43 | 0.310 |
Why?
|
| Cell Cycle | 5 | 2005 | 312 | 0.310 |
Why?
|
| Male | 20 | 2018 | 37283 | 0.280 |
Why?
|
| Molecular Targeted Therapy | 3 | 2015 | 170 | 0.270 |
Why?
|
| Risk Factors | 7 | 2020 | 5720 | 0.270 |
Why?
|
| Sirtuin 1 | 3 | 2011 | 47 | 0.270 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2007 | 102 | 0.270 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2015 | 235 | 0.260 |
Why?
|
| Mice, Knockout | 8 | 2020 | 1692 | 0.260 |
Why?
|
| HT29 Cells | 3 | 2011 | 42 | 0.250 |
Why?
|
| Superoxide Dismutase | 3 | 2012 | 149 | 0.240 |
Why?
|
| Gastrointestinal Tract | 2 | 2018 | 63 | 0.240 |
Why?
|
| Dronabinol | 2 | 2019 | 84 | 0.240 |
Why?
|
| Intestinal Mucosa | 4 | 2019 | 219 | 0.240 |
Why?
|
| Genome | 1 | 2004 | 54 | 0.240 |
Why?
|
| In Situ Nick-End Labeling | 3 | 2012 | 160 | 0.220 |
Why?
|
| Gene Expression Regulation | 3 | 2010 | 1293 | 0.220 |
Why?
|
| Research | 1 | 2004 | 214 | 0.210 |
Why?
|
| Flow Cytometry | 5 | 2011 | 489 | 0.210 |
Why?
|
| Female | 17 | 2019 | 38021 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2010 | 331 | 0.210 |
Why?
|
| Phosphorylation | 6 | 2012 | 1200 | 0.200 |
Why?
|
| Coculture Techniques | 3 | 2015 | 147 | 0.190 |
Why?
|
| Free Radicals | 4 | 2005 | 65 | 0.190 |
Why?
|
| Chemokine CCL2 | 2 | 2012 | 101 | 0.190 |
Why?
|
| Azoxymethane | 2 | 2010 | 28 | 0.190 |
Why?
|
| Sodium Glutamate | 1 | 2020 | 3 | 0.180 |
Why?
|
| High Fructose Corn Syrup | 1 | 2020 | 3 | 0.180 |
Why?
|
| Red Meat | 1 | 2020 | 10 | 0.180 |
Why?
|
| Flavoring Agents | 1 | 2020 | 24 | 0.180 |
Why?
|
| Food Handling | 1 | 2020 | 34 | 0.180 |
Why?
|
| Coloring Agents | 1 | 2020 | 66 | 0.180 |
Why?
|
| Metabolomics | 1 | 2019 | 28 | 0.170 |
Why?
|
| Myocytes, Cardiac | 2 | 2015 | 442 | 0.170 |
Why?
|
| Blotting, Western | 4 | 2009 | 954 | 0.170 |
Why?
|
| Leukocytes | 2 | 2017 | 99 | 0.170 |
Why?
|
| Immunohistochemistry | 4 | 2010 | 1174 | 0.170 |
Why?
|
| Genetic Heterogeneity | 2 | 2015 | 11 | 0.170 |
Why?
|
| Biomarkers | 5 | 2019 | 1593 | 0.160 |
Why?
|
| Macrophage Activation | 2 | 2009 | 75 | 0.160 |
Why?
|
| Titanium | 1 | 2020 | 118 | 0.160 |
Why?
|
| Cannabinoid Receptor Modulators | 2 | 2009 | 16 | 0.160 |
Why?
|
| DNA Glycosylases | 3 | 2009 | 21 | 0.160 |
Why?
|
| Hepatitis, Autoimmune | 2 | 2009 | 22 | 0.160 |
Why?
|
| Immune System | 1 | 2018 | 63 | 0.160 |
Why?
|
| Administration, Oral | 4 | 2015 | 411 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2019 | 1745 | 0.160 |
Why?
|
| Nitric Oxide Synthase | 6 | 2004 | 163 | 0.160 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 186 | 0.160 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2008 | 282 | 0.160 |
Why?
|
| Cell Movement | 2 | 2013 | 630 | 0.150 |
Why?
|
| Epithelial Cells | 3 | 2015 | 431 | 0.150 |
Why?
|
| Double-Blind Method | 2 | 2012 | 1738 | 0.150 |
Why?
|
| Intestinal Diseases | 1 | 2017 | 25 | 0.150 |
Why?
|
| Persian Gulf Syndrome | 1 | 2017 | 27 | 0.150 |
Why?
|
| Mothers | 1 | 2018 | 172 | 0.140 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 163 | 0.140 |
Why?
|
| Cyclins | 4 | 2004 | 50 | 0.140 |
Why?
|
| Oxazolone | 1 | 2016 | 2 | 0.140 |
Why?
|
| T-Lymphocytes | 2 | 2011 | 597 | 0.140 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2004 | 163 | 0.140 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2017 | 114 | 0.140 |
Why?
|
| Comet Assay | 2 | 2008 | 11 | 0.140 |
Why?
|
| Up-Regulation | 4 | 2012 | 682 | 0.130 |
Why?
|
| Drug Discovery | 1 | 2017 | 94 | 0.130 |
Why?
|
| Frontal Lobe | 1 | 2017 | 156 | 0.130 |
Why?
|
| Models, Theoretical | 1 | 2018 | 384 | 0.130 |
Why?
|
| Lung Neoplasms | 1 | 2004 | 1172 | 0.130 |
Why?
|
| Antineoplastic Agents | 3 | 2015 | 1070 | 0.130 |
Why?
|
| Liver Neoplasms | 3 | 2004 | 334 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 786 | 0.120 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2005 | 320 | 0.120 |
Why?
|
| Carcinogenesis | 1 | 2015 | 124 | 0.120 |
Why?
|
| Precision Medicine | 1 | 2015 | 111 | 0.120 |
Why?
|
| Psoriasis | 1 | 2015 | 46 | 0.120 |
Why?
|
| Gene Transfer Techniques | 1 | 2015 | 173 | 0.120 |
Why?
|
| Middle Aged | 7 | 2018 | 21119 | 0.110 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2015 | 155 | 0.110 |
Why?
|
| Cell Separation | 2 | 2011 | 132 | 0.110 |
Why?
|
| Cyclin E | 1 | 2013 | 19 | 0.110 |
Why?
|
| Cyclin D | 1 | 2013 | 12 | 0.110 |
Why?
|
| G1 Phase | 1 | 2013 | 42 | 0.110 |
Why?
|
| DNA Polymerase beta | 2 | 2009 | 9 | 0.110 |
Why?
|
| Phenylglyoxal | 1 | 2012 | 1 | 0.110 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2013 | 145 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2013 | 28 | 0.110 |
Why?
|
| Molecular Probes | 1 | 2012 | 27 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 4 | 2012 | 97 | 0.110 |
Why?
|
| Interleukin-10 | 2 | 2011 | 144 | 0.110 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 307 | 0.110 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2012 | 12 | 0.110 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2012 | 14 | 0.110 |
Why?
|
| I-kappa B Kinase | 1 | 2012 | 40 | 0.110 |
Why?
|
| Chemical Fractionation | 1 | 2012 | 18 | 0.110 |
Why?
|
| Nitric Oxide Donors | 3 | 2007 | 54 | 0.110 |
Why?
|
| Young Adult | 3 | 2017 | 5710 | 0.100 |
Why?
|
| HSP90 Heat-Shock Proteins | 2 | 2010 | 46 | 0.100 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2012 | 59 | 0.100 |
Why?
|
| Protein Isoforms | 1 | 2013 | 246 | 0.100 |
Why?
|
| Micronutrients | 1 | 2012 | 31 | 0.100 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2012 | 59 | 0.100 |
Why?
|
| Endpoint Determination | 1 | 2012 | 82 | 0.100 |
Why?
|
| Cellular Senescence | 1 | 2012 | 112 | 0.100 |
Why?
|
| Receptors, CXCR3 | 1 | 2011 | 16 | 0.100 |
Why?
|
| Receptors, Chemokine | 1 | 2011 | 26 | 0.100 |
Why?
|
| CD11b Antigen | 1 | 2011 | 47 | 0.100 |
Why?
|
| Biological Assay | 1 | 2012 | 88 | 0.100 |
Why?
|
| Receptors, Aryl Hydrocarbon | 2 | 2011 | 46 | 0.100 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 3 | 2009 | 7 | 0.100 |
Why?
|
| Anticarcinogenic Agents | 1 | 2011 | 52 | 0.100 |
Why?
|
| Chemokine CCL4 | 1 | 2010 | 6 | 0.090 |
Why?
|
| beta Carotene | 1 | 2010 | 16 | 0.090 |
Why?
|
| Myeloid Cells | 1 | 2011 | 57 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2010 | 3 | 0.090 |
Why?
|
| PAX2 Transcription Factor | 1 | 2010 | 11 | 0.090 |
Why?
|
| Chemokine CCL5 | 1 | 2010 | 23 | 0.090 |
Why?
|
| Ascorbic Acid | 1 | 2010 | 45 | 0.090 |
Why?
|
| DNA-Binding Proteins | 3 | 2004 | 700 | 0.090 |
Why?
|
| Vitamin E | 1 | 2010 | 55 | 0.090 |
Why?
|
| Lymphoma | 1 | 2011 | 116 | 0.090 |
Why?
|
| Arginine | 1 | 2011 | 102 | 0.090 |
Why?
|
| Spermine | 2 | 2007 | 49 | 0.090 |
Why?
|
| Chronic Disease | 2 | 2012 | 1329 | 0.090 |
Why?
|
| Cyclic GMP | 2 | 2007 | 99 | 0.090 |
Why?
|
| Mutation | 6 | 2004 | 1213 | 0.090 |
Why?
|
| Chronobiology Disorders | 1 | 2009 | 5 | 0.090 |
Why?
|
| Carcinogens | 1 | 2010 | 86 | 0.090 |
Why?
|
| Period Circadian Proteins | 1 | 2009 | 16 | 0.090 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 74 | 0.090 |
Why?
|
| STAT Transcription Factors | 1 | 2009 | 13 | 0.090 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 175 | 0.090 |
Why?
|
| Sleep Deprivation | 1 | 2009 | 81 | 0.080 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2009 | 40 | 0.080 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 214 | 0.080 |
Why?
|
| Lysophospholipids | 1 | 2010 | 209 | 0.080 |
Why?
|
| Respiratory Burst | 1 | 2008 | 6 | 0.080 |
Why?
|
| Ginkgo biloba | 1 | 2008 | 4 | 0.080 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 301 | 0.080 |
Why?
|
| Sphingosine | 1 | 2010 | 315 | 0.080 |
Why?
|
| RNA Interference | 2 | 2010 | 266 | 0.080 |
Why?
|
| Polyunsaturated Alkamides | 1 | 2008 | 17 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 196 | 0.080 |
Why?
|
| Reactive Oxygen Species | 2 | 2008 | 499 | 0.080 |
Why?
|
| Neoplasms, Experimental | 1 | 2008 | 118 | 0.080 |
Why?
|
| Arachidonic Acids | 1 | 2008 | 97 | 0.080 |
Why?
|
| Forkhead Transcription Factors | 1 | 2008 | 94 | 0.080 |
Why?
|
| Guanylate Cyclase | 1 | 2007 | 25 | 0.080 |
Why?
|
| Adult | 4 | 2017 | 21379 | 0.080 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2007 | 34 | 0.080 |
Why?
|
| Cell Proliferation | 2 | 2011 | 1174 | 0.070 |
Why?
|
| Receptors, Estrogen | 1 | 2007 | 142 | 0.070 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2004 | 12 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2007 | 223 | 0.070 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2007 | 110 | 0.070 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2007 | 133 | 0.070 |
Why?
|
| Interferon-gamma | 2 | 2008 | 241 | 0.070 |
Why?
|
| Preventive Medicine | 1 | 2006 | 48 | 0.070 |
Why?
|
| Cell Growth Processes | 1 | 2005 | 40 | 0.070 |
Why?
|
| Arachidonic Acid | 1 | 2005 | 86 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2007 | 183 | 0.070 |
Why?
|
| Community Networks | 1 | 2006 | 96 | 0.070 |
Why?
|
| Feces | 2 | 2019 | 88 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2010 | 626 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 1 | 2007 | 369 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 3256 | 0.060 |
Why?
|
| Breast Neoplasms | 2 | 2007 | 1533 | 0.060 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2005 | 50 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2004 | 194 | 0.060 |
Why?
|
| Sarcoma, Experimental | 1 | 2004 | 5 | 0.060 |
Why?
|
| Nuclear Proteins | 2 | 2004 | 271 | 0.060 |
Why?
|
| Lymphoma, T-Cell | 1 | 2004 | 19 | 0.060 |
Why?
|
| Molecular Epidemiology | 1 | 2004 | 16 | 0.060 |
Why?
|
| Glutathione Peroxidase | 1 | 2004 | 39 | 0.060 |
Why?
|
| Cell Cycle Proteins | 2 | 2004 | 230 | 0.060 |
Why?
|
| Base Pair Mismatch | 1 | 2003 | 12 | 0.060 |
Why?
|
| Aging | 1 | 2010 | 911 | 0.060 |
Why?
|
| Microsatellite Repeats | 1 | 2003 | 40 | 0.060 |
Why?
|
| Body Mass Index | 2 | 2017 | 866 | 0.060 |
Why?
|
| Mice, Transgenic | 3 | 2012 | 1033 | 0.060 |
Why?
|
| Recombination, Genetic | 1 | 2003 | 62 | 0.060 |
Why?
|
| Ataxia Telangiectasia | 1 | 2002 | 1 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2004 | 250 | 0.060 |
Why?
|
| Phosphoserine | 1 | 2002 | 14 | 0.060 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2005 | 306 | 0.050 |
Why?
|
| Hydrogen Peroxide | 3 | 2010 | 168 | 0.050 |
Why?
|
| Health Services Accessibility | 1 | 2006 | 581 | 0.050 |
Why?
|
| Doxorubicin | 3 | 2011 | 231 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 852 | 0.050 |
Why?
|
| Molecular Structure | 2 | 2012 | 397 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2002 | 562 | 0.050 |
Why?
|
| Mucous Membrane | 2 | 2011 | 66 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2002 | 455 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2004 | 301 | 0.050 |
Why?
|
| Kinetics | 2 | 2012 | 1047 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2004 | 753 | 0.040 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2019 | 32 | 0.040 |
Why?
|
| Glycerophospholipids | 1 | 2019 | 20 | 0.040 |
Why?
|
| Injections, Intraperitoneal | 1 | 2019 | 89 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 955 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 65 | 0.040 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 2 | 2012 | 30 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2019 | 222 | 0.040 |
Why?
|
| Time Factors | 4 | 2010 | 4655 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2019 | 284 | 0.040 |
Why?
|
| Fas Ligand Protein | 2 | 2011 | 64 | 0.040 |
Why?
|
| Fibroblasts | 3 | 2012 | 902 | 0.040 |
Why?
|
| Antigens, CD | 2 | 2012 | 230 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2017 | 94 | 0.040 |
Why?
|
| Interleukin-6 | 2 | 2009 | 330 | 0.040 |
Why?
|
| Claudin-2 | 1 | 2017 | 4 | 0.040 |
Why?
|
| Jordan | 1 | 2017 | 4 | 0.040 |
Why?
|
| Gulf War | 1 | 2017 | 22 | 0.040 |
Why?
|
| Endotoxemia | 1 | 2017 | 27 | 0.040 |
Why?
|
| Diet Surveys | 1 | 2017 | 24 | 0.040 |
Why?
|
| Dysbiosis | 1 | 2017 | 24 | 0.040 |
Why?
|
| Nutrition Assessment | 1 | 2017 | 43 | 0.040 |
Why?
|
| Intestines | 1 | 2017 | 114 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2017 | 204 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 710 | 0.030 |
Why?
|
| Smoking | 1 | 2004 | 1449 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 2017 | 215 | 0.030 |
Why?
|
| Plants | 1 | 2015 | 26 | 0.030 |
Why?
|
| Hypertrophy | 1 | 2015 | 89 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2012 | 2673 | 0.030 |
Why?
|
| Cell Hypoxia | 2 | 2005 | 92 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2015 | 61 | 0.030 |
Why?
|
| Body Weight | 1 | 2017 | 554 | 0.030 |
Why?
|
| Rats | 2 | 2015 | 5300 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2015 | 213 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 332 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 1419 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2015 | 291 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1549 | 0.030 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2012 | 14 | 0.030 |
Why?
|
| Rhodamines | 1 | 2012 | 27 | 0.030 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2012 | 27 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2012 | 25 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2005 | 498 | 0.030 |
Why?
|
| Crohn Disease | 1 | 2012 | 38 | 0.030 |
Why?
|
| beta Catenin | 1 | 2012 | 73 | 0.030 |
Why?
|
| Histones | 1 | 2012 | 111 | 0.030 |
Why?
|
| Biological Availability | 1 | 2011 | 79 | 0.020 |
Why?
|
| Serum Amyloid A Protein | 1 | 2011 | 33 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2011 | 111 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 2265 | 0.020 |
Why?
|
| fas Receptor | 1 | 2011 | 54 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2011 | 190 | 0.020 |
Why?
|
| Immunoglobulin A | 1 | 2011 | 79 | 0.020 |
Why?
|
| Exercise | 1 | 2017 | 658 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2011 | 260 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2011 | 138 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 2356 | 0.020 |
Why?
|
| Stem Cells | 1 | 2012 | 248 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2011 | 238 | 0.020 |
Why?
|
| Spleen | 1 | 2011 | 301 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2011 | 420 | 0.020 |
Why?
|
| Oxidants | 1 | 2010 | 48 | 0.020 |
Why?
|
| Mesentery | 1 | 2009 | 17 | 0.020 |
Why?
|
| Tandem Repeat Sequences | 1 | 2009 | 13 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 507 | 0.020 |
Why?
|
| Intestinal Neoplasms | 1 | 2009 | 30 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2004 | 1663 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2009 | 98 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2009 | 99 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2009 | 89 | 0.020 |
Why?
|
| Cell Death | 1 | 2010 | 329 | 0.020 |
Why?
|
| Angiotensin II | 1 | 2010 | 220 | 0.020 |
Why?
|
| Receptor, Cannabinoid, CB2 | 1 | 2009 | 27 | 0.020 |
Why?
|
| DNA Primers | 1 | 2009 | 302 | 0.020 |
Why?
|
| Weight Loss | 1 | 2011 | 319 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2011 | 481 | 0.020 |
Why?
|
| Fatigue | 1 | 2009 | 132 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2009 | 220 | 0.020 |
Why?
|
| Cell Survival | 1 | 2011 | 901 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2009 | 362 | 0.020 |
Why?
|
| Adenoma | 1 | 2009 | 132 | 0.020 |
Why?
|
| Colonoscopy | 1 | 2009 | 156 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 219 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2009 | 258 | 0.020 |
Why?
|
| Concanavalin A | 1 | 2008 | 22 | 0.020 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2009 | 68 | 0.020 |
Why?
|
| Receptors, Cannabinoid | 1 | 2008 | 26 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 2008 | 87 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2009 | 447 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 492 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2009 | 247 | 0.020 |
Why?
|
| Cannabinoids | 1 | 2009 | 90 | 0.020 |
Why?
|
| Endocannabinoids | 1 | 2008 | 32 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2008 | 137 | 0.020 |
Why?
|
| Disease Progression | 1 | 2011 | 1037 | 0.020 |
Why?
|
| Base Sequence | 1 | 2009 | 1015 | 0.020 |
Why?
|
| Chemokines | 1 | 2008 | 119 | 0.020 |
Why?
|
| Genotype | 1 | 2009 | 785 | 0.020 |
Why?
|
| bcl-Associated Death Protein | 1 | 2007 | 19 | 0.020 |
Why?
|
| Caspase 9 | 1 | 2007 | 31 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2011 | 1034 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2007 | 65 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2007 | 46 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2007 | 104 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2008 | 205 | 0.020 |
Why?
|
| Social Justice | 1 | 2006 | 32 | 0.020 |
Why?
|
| Nitrogen Oxides | 1 | 2005 | 7 | 0.020 |
Why?
|
| Program Development | 1 | 2006 | 240 | 0.020 |
Why?
|
| Inbreeding | 1 | 2004 | 4 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2004 | 28 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2004 | 100 | 0.020 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2004 | 65 | 0.020 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2004 | 12 | 0.010 |
Why?
|
| Cytochromes c | 1 | 2004 | 75 | 0.010 |
Why?
|
| Electrochemistry | 1 | 2004 | 70 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 8904 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2004 | 24 | 0.010 |
Why?
|
| Serine | 1 | 2004 | 99 | 0.010 |
Why?
|
| Frameshift Mutation | 1 | 2003 | 8 | 0.010 |
Why?
|
| Densitometry | 1 | 2003 | 15 | 0.010 |
Why?
|
| Survival Rate | 1 | 2007 | 1055 | 0.010 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2004 | 71 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2004 | 118 | 0.010 |
Why?
|
| K562 Cells | 1 | 2003 | 44 | 0.010 |
Why?
|
| Catalase | 1 | 2004 | 85 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2004 | 254 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2004 | 132 | 0.010 |
Why?
|
| Rad51 Recombinase | 1 | 2003 | 16 | 0.010 |
Why?
|
| Chemoprevention | 1 | 2003 | 26 | 0.010 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2002 | 7 | 0.010 |
Why?
|
| DNA Helicases | 1 | 2003 | 64 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 2004 | 199 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2004 | 282 | 0.010 |
Why?
|
| Depression | 1 | 2009 | 942 | 0.010 |
Why?
|
| Liver | 1 | 2008 | 1118 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2003 | 322 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 742 | 0.010 |
Why?
|
| Incidence | 1 | 2006 | 1582 | 0.010 |
Why?
|
| Models, Animal | 1 | 2003 | 252 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 370 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2003 | 305 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 411 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2009 | 2798 | 0.010 |
Why?
|
| Aged | 1 | 2017 | 14842 | 0.010 |
Why?
|
| Protein Binding | 1 | 2003 | 1027 | 0.010 |
Why?
|
| Calcium | 1 | 2004 | 929 | 0.010 |
Why?
|
| South Carolina | 1 | 2006 | 2752 | 0.010 |
Why?
|
| Mitochondria | 1 | 2004 | 643 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2008 | 7028 | 0.010 |
Why?
|